Nawfal, R. Et Al. 2024. 1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens. ANNALS OF ONCOLOGY , vol.35 , 1.

Nawfal, R., Semaan, K., Eid, M., Paul, M., Saliby, R., El Hajj Chehade, R., ... Machaalani, M.(2024). 1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens. ANNALS OF ONCOLOGY , vol.35, 1.

Nawfal, R. Et Al. "1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens," ANNALS OF ONCOLOGY , vol.35, 1, 2024

Nawfal, R. Et Al. "1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens." ANNALS OF ONCOLOGY , vol.35, pp.1, 2024

Nawfal, R. Et Al. (2024) . "1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens." ANNALS OF ONCOLOGY , vol.35, p.1.

@article{article, author={R. Nawfal Et Al. }, title={1705P Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens}, journal={ANNALS OF ONCOLOGY}, year=2024, pages={1} }